A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

Prior treatment

• Antibiotic treatment for an acute respiratory tract infection in the previous 4 weeks or current sinusitis.
• Treatment with anti-coagulants.
  • Bronchiectasis cohort:

Other illness

• Any respiratory diagnosis (asthma, COPD, bronchiectasis, pulmonary fibrosis or any other chronic respiratory condition requiring regular treatment).
• Inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease, any other connective tissue disease.
• Active malignancy excluding non-melanoma skin cancer.
• Traction bronchiectasis associated with interstitial lung disease or other pulmonary disorders (e.g., pulmonary fibrosis and cystic fibrosis).
• Primary diagnosis of another pulmonary condition, including COPD, asthma. Patients with a secondary diagnosis of these pulmonary diseases will be allowed to participate as long as bronchiectasis is considered by the investigator to be the primary diagnosis.
• Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:
• The participant has a history of alcohol or drug abuse within the past year, which, in the opinion of the responsible physician, contra-indicates their participation.
• Active malignancy excluding non-melanoma skin cancer.
• History or current evidence of an upper or lower respiratory infection or symptoms(including common cold) within 2 weeks of baseline assessments
• Terminal disease and/or organ failure or participants otherwise considered not appropriate for the study participation.

Other

• Healthy control cohort:
• Any contraindication to study procedures including bronchoscopy.
• Current smoking or smoking in the preceding 3 months.
• Affect the safety of the participant throughout the study
• Influence the findings of the study or the interpretation
• Impede the participant's ability to complete the entire duration of study
• Participants is female who is pregnant or lactating or up to 6 weeks post-partum or 6 weeks cessation of breastfeeding.
• The participant has an altered mental status at the time of informed consent.
• Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study center).

• Healthy control cohort:
• Age ≥30 years
  • Bronchiectasis cohort:
• Capable of giving signed informed consent.
• Participant must be ≥18 years of age, at the time of signing the ICF.
• Able to perform acceptable lung function testing according to ATS/ERS 2019 acceptability criteria.
• Able and willing to comply with the requirements of the protocol including ability to read, write, be fluent in the translated language of all participants facing questionnaires used at center, and use electronic devices (e.g. FENO and spirometry).
• Documented physician-diagnosed bronchiectasis: with a clinical history consistent with bronchiectasis (chronic cough and daily sputum production etc.) and having performed chest HRCT indicating bronchiectasis.
• Remaining clinically stable upon recruitment. Patients with exacerbations are allowed to be enrolled into the study at least 4 weeks after the end of exacerbations. If a patient experiencing exacerbation and directly enters the exacerbation visit, the patient is required to come to the study site for baseline visit (after confirming that all inclusion/exclusion criteria are met) within 4 weeks /+ 3 days after the end of exacerbation